/
Musculoskeletal
Arthritis
188
Pipeline Programs↗
296
Active Trials↗
177
Companies Involved↗
Arthritis is a highly competitive landscape with 188 programs across 177 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., TJ Biopharma Co., Ltd., XBiotech, Inc.. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical99
Phase 132
Phase 230
Phase 327
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
135 of 160 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 160 classified programs, each share of the total. Modality classified for 96% of 188 pipeline programs.
Analysis
Trial Status
1,918
clinical trials
Completed1,255 · 65%
Terminated167 · 9%
Recruiting159 · 8%
Unknown status144 · 8%
Not yet recruiting71 · 4%
Active, not recruiting58 · 3%
Other64 · 3%
Clinical Trials
Trial Activity
1918 trials
Studies on the Natural History and Pathogenesis of Spondyloarthritis
Recruiting·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·N/A·NCT01422694·2,000 enrolled
Page 1 of 128
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)